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TECHNICAL NOTE

Open Access

GWATCH: a web platform for automated gene
association discovery analysis
Anton Svitin1*†, Sergey Malov1,2†, Nikolay Cherkasov1†, Paul Geerts3, Mikhail Rotkevich1, Pavel Dobrynin1,
Andrey Shevchenko1, Li Guan1, Jennifer Troyer4, Sher Hendrickson5, Holli Hutcheson Dilks6, Taras K Oleksyk7,
Sharyne Donfield8, Edward Gomperts9, Douglas A Jabs10, Efe Sezgin11, Mark Van Natta11, P Richard Harrigan12,13,
Zabrina L Brumme14 and Stephen J O’Brien1,15*

Abstract
Background: As genome-wide sequence analyses for complex human disease determinants are expanding, it is
increasingly necessary to develop strategies to promote discovery and validation of potential disease-gene associations.
Findings: Here we present a dynamic web-based platform – GWATCH – that automates and facilitates four steps
in genetic epidemiological discovery: 1) Rapid gene association search and discovery analysis of large genome-wide
datasets; 2) Expanded visual display of gene associations for genome-wide variants (SNPs, indels, CNVs), including
Manhattan plots, 2D and 3D snapshots of any gene region, and a dynamic genome browser illustrating gene
association chromosomal regions; 3) Real-time validation/replication of candidate or putative genes suggested
from other sources, limiting Bonferroni genome-wide association study (GWAS) penalties; 4) Open data release
and sharing by eliminating privacy constraints (The National Human Genome Research Institute (NHGRI) Institutional
Review Board (IRB), informed consent, The Health Insurance Portability and Accountability Act (HIPAA) of 1996 etc.)
on unabridged results, which allows for open access comparative and meta-analysis.
Conclusions: GWATCH is suitable for both GWAS and whole genome sequence association datasets. We illustrate the
utility of GWATCH with three large genome-wide association studies for HIV-AIDS resistance genes screened in large
multicenter cohorts; however, association datasets from any study can be uploaded and analyzed by GWATCH.
Keywords: AIDS, HIV, Complex diseases, Genome-wide association studies (GWAS), Whole genome sequencing (WGS)

Findings
Introduction

Annotations of human genome variation have identified
some 60 million single nucleotide polymorphisms (SNPs),
which offer the promise of connecting nucleotide and
structural variation to hereditary traits [1-3]. Genotyping
arrays that resolve millions of common SNPs have enabled
over 2,000 genome-wide associations studies (GWAS)
to discover principal genetic determinants of complex
multifactorial human diseases [4,5]. Today, whole-genome
sequence association has extended the prospects for
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personalized genomic medicine, capturing rare variants,
copy number variation (CNV), indels, epistatic and epigenetic interactions in hopes of achieving individualized
genomic assessment, diagnostics, and therapy of complex
maladies by interpreting one’s genomic heritage [6-9].
To date, GWAS studies have produced conflicting signals
because many SNP associations are not replicated in subsequent studies. Further, GWAS frequently fail to implicate
previously-validated gene regions described in candidate
gene associations for the same disease, and in most cases
offer less than 10% of the explanatory variance for the
disease etiology [9-13]. In addition, discovered gene
variants are frequently nested in noncoding desert regions
of the genome that are difficult to interpret. At least
part of these weaknesses derive from discounting SNP
association “hits” that fail to achieve “genome-wide significance”, a widely accepted, albeit conservative, statistical
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threshold set to discard the plethora of false positive
statistical associations (Type I errors) that derive from
the large number of SNPs interrogated [2,13-16].
A challenge to genetic epidemiology involves disentangling the true functional associations that straddle the
genome-wide significance threshold from the myriad of
statistical artifacts that also occur. No one has developed
a real solution to this conundrum, though some approaches
have been offered [11,15-21]. Many researchers agree
that more widely practiced open access data sharing of
unabridged GWAS data would offer the opportunity for
multiple plausible approaches to bear on this question
[22,23]. However, for many cohorts, especially those developed before the advent of the genomics era, participants
were not consented for open access of genome-wide
data. Since patient anonymization is virtually impossible
with genetic epidemiological data, the prospects of sharing
patients’ genotype and clinical data may conflict with
ethical concerns over protecting the individual privacy
of study subjects [24-26]. GWATCH (Genome-Wide
Association Tracks Chromosome Highway) addresses this
issue through an organized open release of unabridged
SNP-test association results from GWAS and whole
genome sequencing (WGS) association studies and illustrates its utility using a SNP association analysis for
HIV-AIDS in multiple cohorts [10,11,19,27-32].

Results
GWATCH is a dynamic genome browser that automates and displays primary analysis results: p-values
and Quantitative Association Statistic (QAS, a general
term for statistics explaining direction and strength of associations: odds ratio, relative hazard and ez2-transformed
correlation coefficient; see Section 2 of Additional file 1:
Materials and Methods) from multiple association tests
performed for one or more cohorts in a GWAS or WGS
association study as a visual array ordered by SNP
chromosomal position [33]. GWATCH offers a number
of “features” that allow automated analysis and visualization
of multiple test results, rapid discovery, replication and
data release of unabridged association results (Table 1).
A typical input of a GWAS analysis includes a large
unabridged Data Table listing p-values and QASs
across multiple SNP association tests performed for a
list of ~10,000,000 ordered SNPs (Additional file 2: Table
S1). GWATCH displays the Data Table, association tests
and various perspectives for results: Manhattan plots for
each single test (Additional File 1: Figure S1), 2D and 3D
snapshots of test results for chromosome regions of “hits”,
and a dynamic chromosome browser that illustrates significant p-values and QASs from the Data Table (Figure 1A, B
and C). The imagery provides a dynamic traverse along a
human chromosome producing a “bird’s eye” view of the
strong SNP associations that rise above the chromosome
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highway surface. The idea is to visualize association
results across a gene region (e.g., one that may include a
highly significant SNP association) for all the tests
performed (on the same or different cohorts) and for all
the neighboring, potentially proxy SNPs (i.e., SNPs which
track the neighboring causal, disease-affecting SNP due to
the linkage disequilibrium [LD]) for the same tests.
Top hits are ranked based upon extreme p-values, QASs,
or “density” of composite p-value peaks (representing proxy
SNPs in linkage disequilibrium and multiple non-independent association tests). A multi-page “TRAX REPORT” produces curves, tables and appropriate statistics for a selected
variant (SNP, indel or CNV tracked) on request. As genotyping and clinical data are organized, GWATCH automates
the computation and visualization of results allowing
instant replication of putative discoveries suggested
by outside cohort studies or functional experiments.
GWATCH also provides a simple procedure for web release of the association results to interested researchers.
We illustrate the utility, interpretation, and navigation of
GWATCH using a GWAS carried out with study participants enrolled in eight prospective HIV-AIDS cohorts,
searching for AIDS Restriction Genes [10,11,19,27-32]. We
performed a GWAS meta-analysis on 5,922 patients with
distinctive clinical outcomes genotyped using an Affymetrix
6.0 genotyping array (700,022 SNPs after quality control
[QC] filters) and parsed into three population groups:
Group A) A select group of 1,527 European American individuals; Group B) A larger group of 4,462 European
American individuals that includes Group A; Group C)
An independent group of 1,460 African American individuals (Table 2). Based upon available clinical information, we performed 123 association tests on Group
A, 144 association tests on Group B, and 60 association tests on Group C (Table 3 and Additional file 3:
Table S2, Additional file 4: Table S3, Additional file 5:
Table S4, Additional file 6: Table S5). The tests include
allele and genotype associations for four stages of AIDS:
HIV acquisition/infection, AIDS progression (including
categorical and survival analyses), AIDS-defining conditions and Highly Active AntiRetroviral Therapy (HAART)
outcomes as described previously [27-32]; however, the
unabridged dataset displayed in GWATCH-AIDS is far
richer. For example, in references [28,31,32] each describes
one association test (implicating the PARD3B, PROX1, and
CCR5-Δ32 AIDS restriction genes respectively); [29,30]
analyze small subsets of the SNPs tested within NEMP
and HDF gene groups, respectively. GWATCH-AIDS
presents complete results for 700,022 SNPs for 327 tests
(Table 3) for 5,922 study participants listed in Table 2.
The first step of data analysis using GWATCH is to
produce a large Data Table listing all SNP names, chromosome coordinates and minor allele frequency (MAF),
with p-values and QASs for each test (Additional file 2:
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Table 1 Display feature components of GWATCH
Features displayed

Illustration

1. Unabridged data table of SNP chromosome coordinates, MAF*, p-value and QAS** for
each SNP for each test

Additional file 2: Table S1

2. Association tests list and Manhattan plots for each test across all SNPs

Additional file 1: Figure S1

3. SNAPSHOTS of SNP-test results in a chromosome region:
1. 2D heat plot snapshot illustrating p-values in any selected chromosome region

Figure 1A and Additional file 1: Figure S2

2. 3D checkerboard plot snapshot illustrating p-values and QAS** in any selected
chromosome region

Figure 1B and Additiona file 1: Figure S3

3. LD-polarized 3D checkerboard snapshot illustrating p-values and QAS** in any selected
chromosome region

Figure 1B and Additional file 1: Figure S4

4. Dynamic HIGHWAY view by chromosome browser illustrating p-values and QAS**

Figure 1C

5. Top association hits:
1. Top hits based on ranked -log p-value

Additional file 10: Table S7

2. Top hits based on ranked QAS**

Additional file 10: Table S7

3. Top hits based on ranked Density of -log p-value within a SNP genomic region

Additional file 10: Table S7

6. TRAX feature:
1. TRAX PAGE – two-page graphic summary illustrating p-values and QAS** for one selected SNP

Additional file 7: Figure S5

2. TRAX REPORT – eleven-page analysis summary with graphs, curves and tables for all association
tests for one selected SNP

Additional file 8: Figure S6

Abbreviations: *MAF minor allele frequency, **QAS quantitative association statistic (OR, RH, ez2-transformed correlation coefficient).

Table S1) plus a description of each test. Results in this
Table are displayed as familiar Manhattan plots for each
test as well as by SNAPSHOT views of chromosome
regions. 2D-SNAPSHOT is a heat plot of ordered
SNP-test results (e.g., ~80 SNPs at 4 kb average distance
for 123 tests in Group A (Table 2) equaling ~10,000 SNPtest combinations) indexed by the p-values from p > 0.05
(light grey) to richer colors for decreasing p-values,
assuring that significant region clusters are more densely
colorful (Figure 1A and Additional file 1: Figure S2).
Similarly a 3D-SNAPSHOT presents a checkerboard
view of a chromosome region whereby the blocks rising
above the surface reflect –log p-value and the color intensity reflects the QAS values with green indicating “resistant”
associations (QAS < 1.0) and red showing “susceptible”
ones (QAS > 1.0) (Figure 1B and Additional file 1: Figure S3
and S4). The moving browser HIGHWAY, a major feature
of GWATCH, scrolls across the entire chromosomes in the
3D view of background statistical “noise” plus interesting
regions of dense elevated blocks (Figure 1C).
Since susceptible/resistant colors are initially indexed
by the minor (less common) allele at any locus, color
discordance will arise in a region when minor allele at a
given locus is tracked in LD by the common allele at an
adjacent locus. The POLARIZE option corrects this
computational artifact by inverting the QAS in locus
pairs that show discrepant (common and minor allele
tracking as proxies) LD polarity. When the entire association signal for a region, driving the non-independent
SNPs and non-independent tests, derives from a single
causal allele within the region, the blocks of associated

SNPs in the viewed region should be the same color after
polarization (Figure 1B and Additional file 1: Figure S4).
Automated searches for extreme locus “hits” revealing
remarkable associations across the genome can be performed for each stage of disease (see above) screening
for extreme p-values, QAS values and/or density of
extreme p-values. For loci of particular interest, a detailed
TRAX REPORT is generated to display each curve, table
and statistic that had driven the association discovery
(Additional file 7: Figure S5 and Additional file 8: Figure
S6). TRAX REPORT is available for 641 SNPs in 241
genes listed in Additional file 9: Table S6. For the rest
of the SNPs, the TRAX PAGE (shorter version of
TRAX REPORT) is available.
To demonstrate GWATCH, three previously validated
AIDS resistance gene regions, CCR5-Δ32, PROX1 and
PARD3B, can be examined by simple entering rs-number,
gene name or chromosome coordinates in the search
option (see also 2D and 3D snapshots in Additional file 1:
Figures S2-S4). GWATCH moves HIGHWAY to the
selected region so one can visualize the signal with the
2D and 3D-SNAPSHOTS plus the TRAX REPORTS.
Lastly, we also include a listing of discovered regions
that showed AIDS association signals that, though they
did not reach genome-wide significance, represented
outlier values for several related tests and linked SNPs
(Additional file 10: Table S7). These regions then would
be considered as candidates for future evaluation and
replication in independent cohort studies.
Finally, GWATCH is a generalizable web tool suitable
for GWAS and/or WGS dataset for any complex disease.
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Figure 1 (See legend on next page.)
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(See figure on previous page.)
Figure 1 GWATCH produces different kinds of snapshots and views for selected genomic region. (A) 2D-SNAPSHOT of PARD3B region of
Chromosome 2 [28] tested for the 123 tests in Group A (Table 2). (B) POLARIZED 3D-SNAPSHOT of the PROX1 region of Chromosome 1 [31]
tested for the same group (Table 2). (C) Dynamic 3D HIGHWAY chromosome browser view of CCR5 region of Chromosome 3 [32] tested for the
same group (Table 2). See also in Additional file 1: Figures S2-S4.

The “finished“or “processed” data (ones containing a final
Data Table of p-values and QAS for completed association
tests) can be uploaded directly by following instructions
for dataset upload on the GWATCH website. “Primary” or
“unfinished” data (ones with genotypes and clinical data
for which tests need to be constructed and calculated) will
be uploaded with our assistance in custom development
of a disease-specific GWATCH-based analysis.

Discussion
GWATCH is designed to enable investigators and users
not connected to the original study to access the results
of SNP association (from the whole genome sequence
or SNP array genotyping) in order to view and share
their study design and results openly. It can be used for
visualization of regions with low p-values to inspect
the pattern of variation across linked SNPs and also at
different stages of disease (e.g., HIV infection, AIDS
progression and treatment outcome).
As a primary discovery approach, screening across
unabridged test results poses large statistical penalties
for multiple tests eroding confidence in associations that
fail to achieve genome-wide significance [2,13-18,21]. For
this reason, one should use caution in inspection of
putative regions of significance. Nonetheless, wholesale
discarding of marginally significant “hits” will discount
some true associations within the mix of statistical
artifacts. GWATCH offers an opportunity to screen the
genome for disease-associated regions, which may contain
causal SNP variants included (or not) in the SNP array
used for genotyping, as well as proxy SNPs tracking the
causal variant. Further, in complex diseases for which
there are many different cohorts being studied (e.g., in

HIV-AIDS there are at least twenty different groups conducting AIDS GWAS on small, well-defined cohorts that
may differ in genetic background and clinical data available for association testing) [34] GWATCH offers rapid
replication opportunities with an independent dataset.
There are several websites that aim at cataloguing and
displaying SNP associations. For example, GWAS Central
[35] is a valuable resource for releasing and accessing
GWAS data [36]. At the same time, we believe that
GWATCH can be advantageous in some cases for the
following reasons: 1) GWATCH utilizes (while not revealing directly) primary unabridged clinical/phenotypic
data providing detailed analytical reports, like TRAX,
not offered in GWAS Central; 2) GWATCH contains
summary tools, such as top hits tables, and performs
calculation of density that allows for identification,
inspection and replication of putative association hits;
3) GWAS Central reports traditional Manhattan plots
while GWATCH extends these to 2D and 3D static and
dynamic region visuals that expands user comprehension
and perception for better grasp of large data.
The GWATCH web browser provides a dynamic visual
journey, similar to driving a video game along human
chromosomes to view patterns of GWAS- or WGS-based
variant association with any complex disease. It is meant
to be appealing, intuitive, and accessible to non-experts
and experts alike, including the various contributors to
today’s exciting gene association studies. The format and
open web access allows for importing new data from any
disease-gene association study with multiple disease stages
or genetic models of analysis. The wide breadth of test
associations displayed is particularly suited to complex
disease cohorts with detailed clinical parameters over

Table 2 Categories and numbers of patients genotyped in AIDS GWAS meta-analysis
Abbreviations

HREU

Risk groups

High Risk Exposed HIV Uninfected

EU (except HREU)

Exposed HIV Uninfected (all risks)

SC

Sero-Convertor

Number of patients for each group

Total

Group A

Group B

Group C

EA*-I

EA*-Total

AA**

B+C

254

300

148

1

351

267

618

703

767

288

1 055

448

SP-LTS

Sero-Prevalent-Long-Term-Survivor (no AIDS for >10 years)

444

831

170

1 001

Sequelae

AIDS sequelae diagnosis

461

1 848

0

1 848

HAART

Anti-retroviral treatment

485

1 319

65

1 384

1 527

4 462

1 460

5 922

Total study participants
Abbreviations: *EA European Americans, **AA African Americans.
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Table 3 Statistical tests performed on 3 HIV-AIDS cohort Study Groups A-C (see Table 2)
Clinical stage

Test type

Number of tests for each group
Group A

Group B

Group C

3

12

12

I. HIV Infection

Ia. Infection - categorical

II. HIV Progression

IIa. Progression - categorical dichotomous

12

12

12

IIb. Progression - categorical multipoint

12

12

12

IIc. Progression - survival

48

48

24

IIIa. Sequelae - categorical first sequela

9

9

-

IIIb. Sequelae - survival first sequela

9

-

-

IIIc. Sequelae - categorical any sequelae

9

33

-

IIId. Sequelae - survival any sequelae

9

6

-

IVa. HAART - categorical

6

-

-

III. AIDS-defining Conditions

IV. Treatment with ARV

IVb. HAART - survival
Total

6

12

-

123

144

60

See Additional file 3: Table S2, Additional file 4: Table S3, Additional file 5: Table S4, Additional file 6: Table S5, for detailed description of statistical association
tests performed in each group.

distinct disorder stages. Further, although GWATCH is
potentially useful for initial gene discovery, an important
corollary lies in providing rapid replication of gene
discoveries from independent cohort studies by simply
keying in the putative gene region and inspecting the
many test results of the posted dataset. Since replication
screens are hypothesis-driven, they avoid the stringent
multiple test correction penalties of a GWAS/WGS
(p < 10−8). Finally, different cohort studies can be compared directly or combined to build meta-analyses.
Should many cohort investigators release their unabridged results, then association discoveries will be replicated (or not) in a rapid, open and productive manner,
allowing for large meta-analyses as have been proposed
for HIV-AIDS and other complex diseases [22,23,34].
Unlike other methods of data sharing, this resultsbased open data sharing/release approach avoids any
violation of patient privacy, IRB (institutional review
board) and HIPAA (Health Insurance Portability and
Accountability Act of 1996) concerns, or informed consent
constraints, since the primary clinical and genotype data
remain confidential while the derivative results (p-values,
QASs, plots) of multiple conceivable analytical approaches
are openly released. In this approach, we hope to considerably expand discovery and replication opportunities
in important biomedical research. To us, this ensures
the maximum benefit of open access data sharing while
protecting patients who prefer privacy (many do), but
wish to see their volunteerism fulfilled.

Materials and methods

engine and Java-based toolkit Batik. R-project functions
and modules are used for performing statistical tests,
polarization and density calculation. MySQL database
component of GWATCH allows access, retrieval and
management of genotypes, clinical information and test
results. On the frontend, GWATCH employs HTML5,
Javascript, jQuery and WebGL for HIGHWAY browser
interface, and Ajax and JSON technologies for data
exchange between server and client.
GWATCH tools
TRAX REPORTS

After screening for associations of clinical traits and genotypes one may be interested in a closer review of certain
SNPs. The TRAX REPORT (Additional file 7: Figure S5
and Additional file 8: Figure S6) tool allows the production
of reports on extended statistical analysis for any single
SNP if the corresponding genotype and clinical information
is available for all individuals. Important genotype information is given in the header on the TRAX front page: SNP
identifier, SNP coordinate, chromosome, alleles and their
frequencies. The header also lists information on populations involved in the analysis. In addition to the header,
front page also contains a summary for all tests with pvalues, as well as values of QAS represented in the bar plot
form. The following pages of TRAX REPORT contain
detailed information, such as contingency tables (that are
produced in the form of corresponding bar plots for any
categorical test, including progression categorical tests),
and Kaplan–Meier survival curves that are reported for all
three genotypes for all survival tests.

GWATCH implementation

GWATCH is a web-based application that integrates several technologies and programming languages. Server-side
is represented by Apache web server, which employs PHP

Polarization

The polarization tool enables the inversion of test results
for minor and common SNP-alleles around some fixed
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SNP (called index SNP) for better approximation of
true associations. A polarization table is produced using
linkage disequilibrium coefficients (D’) between neighboring SNPs. Linkage disequilibrium coefficients are calculated
for 80 SNPs upstream and 80 SNPs downstream of the
index SNP. In the case of a sufficiently large positive value
of linkage disequilibrium (D’ > 0.9), the polarization mark is
assigned to 1, whereas in the case of a sufficiently large
negative linkage disequilibrium (D’ < −0.9) the polarization
mark is assigned to −1. If the linkage disequilibrium is
sufficiently small, the polarization mark is assigned to 0.
In the process of polarization, QAS values for test results
of neighboring SNPs are inverted if the polarization
mark is −1 implying the inversion of direction of disease
association for such SNPs.
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software in European and African American populations
[39] and structured SNP variants were excluded [28,39].
The statistical tests described below and listed in
Table 3 and Additional file 3: Table S2, Additional file 4:
Table S3, Additional file 5: Table S4 and Additional file 6:
Table S5, were applied to the three patient study groups
A, B and C (see Table 2). For each of the tests described
below three genetic models were used (D, R and CD, see
in Section 1 of Supplementary Materials and Methods
under “Genotype classification” in Additional file 1)
unless stated otherwise.
Infection tests (INF)

The second step can be performed for all the tests or
for the group of tests by the disease stage (e.g., all tests
for HIV infection, all tests for AIDS progression etc.).

The aim of infection tests is to specify association of any
selected genotype with HIV infection. The original clinical
data is of categorical type based on the population of
seronegatives (SN, individuals which stay HIV-negative
throughout the whole study) at the baseline with the
response variable indicating serostatus at the endpoint
and having three levels: “high risk exposed uninfected”
(HREU) seronegatives, “other seronegatives” (OSN) and
“seroconverters” (SC, individuals which entered the study
as HIV-negative, but became HIV-positive during the
study). Three combinations of HIV status classifications
were used to perform the categorical tests: “SC” vs.
“HREU”, “SC” vs. “HREU” plus “OSN” and “SC” vs.
“HREU” vs. “OSN”. In addition to the three genotype
classifications described above (D, R and CD), allelic
model (A) was also used for this test. One more group
of individuals based on infection status, “seroprevalents”
(SP, individuals which entered the study already being
HIV-positive), was not informative for this type of test and
therefore was not included in it.

Statistical tests and data used for complex AIDS study

Disease progression tests

General types of statistical data and tests relevant to
GWATCH are described in Additional file 1: Materials
and Methods. Below we describe particular tests and
data types used in the exemplary analysis of HIV/AIDS
study data.
To illustrate GWATCH utility in the analysis of GWAS
results we used data from multicenter longitudinal studies
of several cohorts of patients exposed to the risk of HIV
infection and/or already infected with HIV: ALIVE, DCG,
HGDS, HOMER, LSOCA, MACS, MHCS and SFCC
[11,34,37,38]. The total pool of patients was divided into
three groups A, B and C based on ethnicity and timing of
data development (see Table 2). A total of 5,922 patients
were analyzed in all 3 groups.
All patient samples and genotypes were subjected to
QC filtering depicted in Additional file 1: Table S8 as
described previously [28,31]. Once final genotypes were
obtained, population structure was assessed using the
Principal Components Analysis module of Eigensoft

The disease progression tests were used for screening
significant associations between AIDS progression and
genotype. The original data were of right-censored survival
type under four different criteria of AIDS disease: CD4 <
200 (level of CD4+ cells falling below 200 cells/mm3),
AIDS-1987 (patient meeting criteria of 1987 CDC definition of AIDS), AIDS-1993 (patient meeting criteria of 1993
CDC definition of AIDS) and Death from AIDS. Only
SC and SP individuals were included in this analysis. SC
individuals were included into analysis with HIV infection date (date of seroconvertion) as the baseline. SP
individuals were included into categorical analysis with
the date of the first visit as the baseline with some
warnings.
Disease progression categorical analysis (PDCA) used
the categorical tests for survival data (CTSD) approach
described in Section 2 of Additional file 1: Materials and
Methods. The CTSD were performed in dichotomous
(PDCA2, two groups by the survival time or current

Density

Density top scoring that identifies regions of concentration of small p-values is calculated for each SNP in two
steps:
1) in the window of specified size (n SNPs upstream
and downstream or n Kbp upstream and
downstream) average -log p-value is computed for
each test (lane of the Highway)
2) these per-test (per-lane) averages are used for
calculating density at this SNP either by averaging
them or by finding the largest one (depending on
the option chosen)
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status data) and multipoint (PDCAM, more than two
groups by the survival time) forms. All individuals censored
before the breakpoint were removed from the PDCA
dichotomous analysis, as well as the SP individuals who
failed before the breakpoint. All remaining individuals
censored or failed after the breakpoint were classified
into the group of long-term survivors (LTS, those who
do not show AIDS symptoms before the breakpoint).
The breakpoints used for classification in multipoint
PDCA are stated in Additional file 3: Table S2, Additional
file 4: Table S3, Additional file 5: Table S4.
Proportional hazard (PHAZ) analysis of disease progression used the proportional hazards survival tests
(PHST) approach described in Section 2 of Additional
file 1: Materials and Methods. These tests were performed
for all four criteria of AIDS. Only SC individuals were
included into PHAZ analysis.
Sequelae tests

Survival and categorical tests were performed for survival
data on Kaposi’s sarcoma (KS), Pneumocystis carnii pneumonia (PCP), cytomegalovirus infection (CM), lymphoma
(LY), mycobacterial infection (MYC) and other opportunistic infections (OOI). As in progression disease tests,
survival sequelae tests included seroconverters only, while
categorical sequelae tests included both seroconverters
and seroprevalents.
Sequelae tests for any infection order classify patients
based on whether specific sequela occurred at all, irrespectively of its order (i.e., whether it was the first sequela
to occur for patient). The survival tests (SEQSA) under
proportional hazards model as well as the progression
categorical tests (SEQCA) were performed separately
for each of the diseases described above.
Sequelae tests for the first infection classify patients based
on whether specific sequela occurred first or not. The
survival tests (SEQS1) under proportional hazards model as
well as the progression categorical tests (SEQC1) were performed separately for each of the diseases described above.
Highly active antiretroviral therapy (HAART) tests

HAART tests were performed for the cohorts of patients
who were subject to this type of treatment. Patients were
classified based on either the level of suppression of HIV
viral load or on the rebound of viral load following its
suppression. Both survival (HRTS) and progression
categorical (HRTC) tests were used for this analysis.
Hardy–Weinberg equilibrium (HWE) tests

The HWE tests are performed to control for the quality of
data used for the screening of associations. Large deviations from HWE are not typical for the large populations
and thus signal the genotyping error or some other type
of data quality breach.
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Availability and requirements
Project name: GWATCH
Project home page: gen-watch.org
https://github.com/DobzhanskyCenter/GWATCH
Operating system(s): Platform independent (runs in the
web browser)
Programming language: HTML5, Javascript, PHP, Java,
R, MySQL
Other requirements: WebGL-supporting web browser
(Firefox 4.0 and above; Chrome 12 and above; under OS
X runs also in Safari 5.1 and above)
License: GPL v2.0
Any restrictions to use by non-academics: no
Availability of supporting data
Archive of the version of GWATCH used in this
paper is available from the GigaScience database [40],
and for the most recent version please see our
GitHub repository.
Additional files
Additional file 1: Supplementary Information. Contains Materials and
Methods, Figures S1–S4, legends for Figure S5 and S6, legends for Table
S1–S7, Table S8 and References.
Additional file 2: Table S1. Data Table of GWAS results: 100 rows of
the Data Table containing SNPs, p-values and QASs for AIDS Restriction
Genes dataset in Study Group A in the PARD3B region of chromosome 2.
Full unabridged data tables for Groups A-C are available on the GWATCH
web portal [33].
Additional file 3: Table S2. List of SNP association statistical tests and
patient counts for Study Group A.
Additional file 4: Table S3. List of SNP association statistical tests and
patient counts for Study Group B.
Additional file 5: Table S4. List of SNP association statistical tests and
patient counts for Study Group C.
Additional file 6: Table S5. Summary of SNP association tests
performed for each Study Group.
Additional file 7: Figure S5. TRAX PAGE, 2 page summary or all test
results for a single SNP for a study group (e.g. p-values and QASs for HIV
infection, AIDS progression using categorical and survival tests, AIDS
sequelae, and HAART outcomes can be viewed and compared). TRAX
PAGE can be generated de novo for any SNP of interest by placing mouse
tip over a significant tower/block in the HIGHWAY and selecting the
TRAX PAGE option from the data window that appears (SNPs for which
TRAX REPORT is available do not have separate TRAX PAGE option in data
window since TRAX REPORT includes TRAX PAGE content).
Additional file 8: Figure S6. Detailed 11 page TRAX REPORT of derived
statistics for all the tests accomplished including tables, bar graphs,
survival curves and additional parameters for each test. TRAX REPORT can
be generated de novo for the SNP of interest by placing mouse tip over a
significant tower/block in HIGHWAY and selecting the TRAX REPORT
option from the data window that appears. TRAX REPORTs are available
for 641 SNPs in 241 human genes that were genotyped to replicate the
GWAS associations for Study Groups A-C (Additional file 9: Table S6).
Additional file 9: Table S6. List of 641 SNPs within 241 human genes
that were assessed to replicate the GWAS associations for Study Groups
A-C. For each of these SNPs a full TRAX REPORT (11 page report of figures
and tables for each test) is available on the GWATCH web portal [33] as
illustrated in Additional file 8: Figure S6.
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Additional file 10: Table S7. Genomic regions of remarkable statistical
association (HITS) identified in ARG-GWAS by the screen for extreme
p-values.

Abbreviations
AIDS: Acquired immunodeficiency syndrome; CDC: Centers for Disease
Control and Prevention; CNV: Copy-number variation; CTSD: categorical
tests for survival data; GWAS: Genome-wide association study; GWATCH:
Genome-Wide Association Tracks Chromosome Highway; HAART: Highly
Active Antiretroviral Therapy; HIPAA: The Health Insurance Portability and
Accountability Act of 1996; HIV: Human immunodeficiency virus; HREU: High
risk exposed uninfected; HTML5: Hypertext markup language, revision 5;
IRB: Institutional Review Board; HWE: Hardy-Weinberg equilibrium;
LD: Linkage disequilibrium; LTS: Long-term survivor; MAF: Minor allele
frequency; OSN: Other seronegatives; QAS: Quantitative Association Statistic;
QC: Quality control; PDCA: Disease progression categorical analysis;
PHAZ: Proportional hazard; PHP: Hypertext Preprocessor; SC: Seroconverter;
SN: Seronegative; SNP: Single nucleotide polymorphism; SP: Seroprevalent;
WGS: Whole genome sequencing.
Competing interests
ASv, SM, NC, PG and SJO are authors of the provisional application for patent
US 61/897,524 “Visualization, sharing and analysis of large data sets” filed on
10/30/2013.
Authors’ contributions
ASv, SM, NC, PG, MR, PD, ASh, TKO and SJO developed GWATCH. LG, JT, SH,
HHD, ES and SJO performed the original GWAS studies. SD, EG, DAJ, MVN,
RH and ZLB contributed new epidemiological data from their AIDS cohorts.
ASv, SM, NC and SJO wrote the manuscript. All authors read and approved
the final manuscript.
Acknowledgements
We gratefully acknowledge the prior collaborative contribution of the patients,
health care givers and investigators of HIV-AIDS cohorts who developed and
catalogued the demographic information used in this illustration.
This work was supported in part by Russian Ministry of Science Mega-grant No.
11.G34.31.0068; Stephen J. O’Brien, Principal Investigator. The Hemophilia
Growth and Development Study is funded by the National Institutes of Health,
National Institute of Child Health and Human Development, R01-HD-41224.
This work was supported by the National Eye Institute, National Institutes of
Health (grants U10EY008052, U10EY008057, and U10EY008067). ZLB is
supported by a New Investigator Award from the Canadian Institutes for
Health Research and a Scholar Award from the Michael Smith Foundation
for Health Research.
Author details
1
Theodosius Dobzhansky Center for Genome Bioinformatics, St. Petersburg
State University, St. Petersburg 199004, Russia. 2Department of Mathematics,
St. Petersburg Electrotechnical University, St. Petersburg 197376, Russia.
3
Scientific Data Visualization Consultant, Turner, ACT 2612, Australia.
4
Genetics and Genomics Group, Advanced Technology Program,
SAIC-Frederick, National Cancer Institute, Frederick, MD 21702, USA.
5
Department of Biology, Shepherd University, Shepherdstown, WV 25443,
USA. 6Vanderbilt Technologies for Advanced Genomics, Office of Research,
Vanderbilt University Medical Center, Nashville, TN 37204, USA. 7Biology
Department, University of Puerto Rico, Mayaguez, PR 00680, USA.
8
Department of Biostatistics, Rho, Inc., Chapel Hill, NC 27517, USA. 9Division
of Hematology-Oncology, Children’s Hospital of Los Angeles, Los Angeles,
CA 90027, USA. 10Departments of Ophthalmology and Medicine, Icahn
School of Medicine at Mount Sinai, New York, NY 10029, USA. 11Department
of Epidemiology, The Johns Hopkins University Bloomberg School of Public
Health, Baltimore, MD 21205, USA. 12British Columbia Centre for Excellence in
HIV/AIDS, Vancouver, BC V6Z 1Y6, Canada. 13Division of AIDS, Faculty of
Medicine, University of British Columbia, Vancouver, BC V6T 1Z3, Canada.
14
Faculty of Health Sciences, Simon Fraser University, Burnaby, BC V5A 1S6,
Canada. 15Oceanographic Center, Nova Southeastern University, Ft.
Lauderdale, FL 33004, USA.

Page 9 of 10

Received: 6 June 2014 Accepted: 30 September 2014
Published: 5 November 2014

References
1. 1000 Genomes Project Consortium, Abecasis GR, Auton A, Brooks LD,
DePristo MA, Durbin RM, Handsaker RE, Kang HM, Marth GT, McVean GA:
An integrated map of genetic variation from 1,092 human genomes.
Nature 2012, 491:56–65.
2. Wellcome Trust Case Control Consortium: Genome-wide association study
of 14,000 cases of seven common diseases and 3,000 shared controls.
Nature 2007, 447:661–678.
3. International HapMap 3 Consortium, Altshuler DM, Gibbs RA, Peltonen L,
Altshuler DM, Gibbs RA, Peltonen L, Dermitzakis E, Schaffner SF, Yu F,
Peltonen L, Dermitzakis E, Bonnen PE, Altshuler DM, Gibbs RA, de Bakker PI,
Deloukas P, Gabriel SB, Gwilliam R, Hunt S, Inouye M, Jia X, Palotie A, Parkin
M, Whittaker P, Yu F, Chang K, Hawes A, Lewis LR, Ren Y, et al: Integrating
common and rare genetic variation in diverse human populations.
Nature 2010, 467:52–58.
4. Hindorff LA, MacArthur J, Morales J, Junkins HA, Hall PN, Klemm AK,
Manolio TA: A Catalog of Published Genome-Wide Association Studies.
[http://www.genome.gov/gwastudies]
5. Hindorff LA, Sethupathy P, Junkins HA, Ramos EM, Mehta JP, Collins FS,
Manolio TA: Potential etiologic and functional implications of genome-wide
association loci for human diseases and traits. Proc Natl Acad Sci 2009,
106:9362–9367.
6. Jiang YH, Yuen RK, Jin X, Wang M, Chen N, Wu X, Ju J, Mei J, Shi Y, He M,
Wang G, Liang J, Wang Z, Cao D, Carter MT, Chrysler C, Drmic IE, Howe JL,
Lau L, Marshall CR, Merico D, Nalpathamkalam T, Thiruvahindrapuram B,
Thompson A, Uddin M, Walker S, Luo J, Anagnostou E, Zwaigenbaum L,
Ring RH, et al: Detection of clinically relevant genetic variants in autism
spectrum disorder by whole-genome sequencing. Am J Hum Genet 2013,
93:249–263.
7. Kilpivaara O, Aaltonen LA: Diagnostic cancer genome sequencing and the
contribution of germline variants. Science 2013, 339:1559–1562.
8. Wade CH, Tarini BA, Wilfond BS: Growing up in the genomic era:
implications of whole-genome sequencing for children, families, and
pediatric practice. Annu Rev Genomics Hum Genet 2013, 14:535–555.
9. Cirulli ET, Goldstein DB: Uncovering the roles of rare variants in common
disease through whole-genome sequencing. Nat Rev Genet 2010,
11:415–425.
10. Hutcheson HB, Lautenberger JA, Nelson GW, Pontius JU, Kessing BD,
Winkler CA, Smith MW, Johnson R, Stephens R, Phair J, Goedert JJ, Donfield
S, O’Brien SJ: Detecting AIDS restriction genes: from candidate genes to
genome-wide association discovery. Vaccine 2008, 26:2951–2965.
11. O’Brien SJ, Nelson GW: Human genes that limit AIDS. Nat Genet 2004,
36:565–574.
12. Bushman FD, Malani N, Fernandes J, D'Orso I, Cagney G, Diamond TL, Zhou H,
Hazuda DJ, Espeseth AS, König R, Bandyopadhyay S, Ideker T, Goff SP, Krogan
NJ, Frankel AD, Young JA, Chanda SK: Host cell factors in HIV replication:
meta-analysis of genome-wide studies. PLoS Pathog 2009,
5:e1000437.
13. Goldstein DB: Common genetic variation and human traits. N Engl J Med
2009, 360:1696–1698.
14. Conneely KN, Boehnke M: So many correlated tests, so little time! Rapid
adjustment of P values for multiple correlated tests. Am J Hum Genet
2007, 81:1158–1168.
15. McCarthy MI, Abecasis GR, Cardon LR, Goldstein DB, Little J, Ioannidis JP,
Hirschhorn JN: Genome-wide association studies for complex traits:
consensus, uncertainty and challenges. Nat Rev Genet 2008, 9:356–369.
16. Johnson RC, Nelson GW, Troyer JL, Lautenberger JA, Kessing BD, Winkler CA,
O'Brien SJ: Accounting for multiple comparisons in a genome wide
association study (GWAS). BMC Genomics 2010, 11:724.
17. Ioannidis JP, Thomas G, Daly MJ: Validating, augmenting and refining
genome-wide association signals. Nat Rev Genet 2009, 10:318–329.
18. Moskvina V, Schmidt KM: On multiple-testing correction in genome-wide
association studies. Genet Epidemiol 2008, 32:567–573.
19. O’Brien SJ, Hendrickson S: Host genomic influences on HIV/AIDS. Genome Biol
2013, 14:201.
20. Dudbridge F, Gusnanto A: Estimation of significance thresholds for
genome wide association scans. Genet Epidemiol 2008, 32:227–234.

Svitin et al. GigaScience 2014, 3:18
http://www.gigasciencejournal.com/content/3/1/18

21. Best practices in GWAS. In Genome Technology Supplemental report 2009.
[http://www.genomeweb.com/node/917734]
22. Johnson AD, O’Donnell CJ: An open access database of genome-wide
association results. BMC Med Genet 2009, 10:6.
23. Hayden EC: Geneticists push for global data-sharing. Nature 2013, 498:16–17.
24. Greely HT: The uneasy ethical and legal underpinnings of large-scale
genomic biobanks. Annu Rev Genomics Hum Genet 2007, 8:343–364.
25. O’Brien SJ: Stewardship of human biospecimens, DNA, genotype, and
clinical data in the GWAS era. Annu Rev Genomics Hum Genet 2009,
10:193–209.
26. Gymrek M, McGuire AL, Golan D, Halperin E, Erlich Y: Identifying personal
genomes by surname inference. Science 2013, 339:321–324.
27. O’Brien SJ, Nelson GW, Winkler CA, Smith MW: Polygenic and multifactorial
disease gene association in man: Lessons from AIDS. Annu Rev Genet
2000, 34:563–591.
28. Troyer JL, Nelson GW, Lautenberger JA, Chinn L, McIntosh C, Johnson RC,
Sezgin E, Kessing B, Malasky M, Hendrickson SL, Li G, Pontius J, Tang M, An
P, Winkler CA, Limou S, Le Clerc S, Delaneau O, Zagury JF, Schuitemaker H,
van Manen D, Bream JH, Gomperts ED, Buchbinder S, Goedert JJ, Kirk GD,
O'Brien SJ: Genome-wide association study implicates PARD3B-based
AIDS restriction. J Infect Dis 2011, 203:1491–1502.
29. Hendrickson SL, Lautenberger JA, Chinn LW, Malasky M, Sezgin E, Kingsley LA,
Goedert JJ, Kirk GD, Gomperts ED, Buchbinder SP, Troyer JL, O’Brien SJ: Genetic
variants in nuclear-encoded mitochondrial genes influence AIDS
progression. PLoS One 2010, 5:e12862.
30. Chinn LW, Tang M, Kessing BD, Lautenberger JA, Troyer JL, Malasky MJ,
McIntosh C, Kirk GD, Wolinsky SM, Buchbinder SP, Gomperts ED, Goedert JJ,
O’Brien SJ: Genetic associations of variants in genes encoding
HIV-dependency factors required for HIV-1 infection. J Infect Dis 2010,
202:1836–1845.
31. Herbeck JT, Gottlieb GS, Winkler CA, Nelson GW, An P, Maust BS, Wong KG,
Troyer JL, Goedert JJ, Kessing BD, Detels R, Wolinsky SM, Martinson J,
Buchbinder S, Kirk GD, Jacobson LP, Margolick JB, Kaslow RA, O'Brien SJ,
Mullins JI: Multistage genomewide association study identifies a locus at
1q41 associated with rate of HIV-1 disease progression to clinical AIDS.
J Infect Dis 2010, 201:618–626.
32. Dean M, Carrington M, Winkler C, Huttley GA, Smith MW, Allikmets R,
Goedert JJ, Buchbinder SP, Vittinghoff E, Gomperts E, Donfield S, Vlahov D,
Kaslow R, Saah A, Rinaldo C, Detels R, O’Brien SJ: Genetic restriction of
HIV-1 infection and progression to AIDS by a deletion allele of the CKR5
structural gene. Science 1996, 273:1856–1862.
33. GWATCH: Genome-Wide Association Tracks Chromosome Highway.
[http://gen-watch.org]
34. McLaren PJ, Coulonges C, Ripke S, van den Berg L, Buchbinder S, Carrington
M, Cossarizza A, Dalmau J, Deeks SG, Delaneau O, De Luca A, Goedert JJ,
Haas D, Herbeck JT, Kathiresan S, Kirk GD, Lambotte O, Luo M, Mallal S, van
Manen D, Martinez-Picado J, Meyer L, Miro JM, Mullins JI, Obel N, O'Brien SJ,
Pereyra F, Plummer FA, Poli G, Qi Y, et al: Association study of common
genetic variants and HIV-1 acquisition in 6,300 infected cases and 7,200
controls. PLoS Pathog 2013, 9:e1003515.
35. GWAS Central. [www.gwascentral.org]
36. Beck T, Hastings RK, Gollapudi S, Free RC, Brookes AJ: GWAS Central: a
comprehensive resource for the comparison and interrogation of
genome-wide association studies. Eur J Hum Genet 2014, 22:949–952.
37. Sezgin E, van Natta ML, Ahuja A, Lyon A, Srivastava S, Troyer JL, O'Brien SJ,
Jabs DA, Studies of the ocular complications of AIDS research group:
Association of host genetic risk factors with the course of
cytomegalovirus retinitis in patients infected with human
immunodeficiency virus. Am J Ophthalmol 2011, 151:999–1006.e4.
38. Harris M, Nosyk B, Harrigan R, Lima VD, Cohen C, Montaner J:
Cost-effectiveness of antiretroviral therapy for multidrug-resistant HIV:
past, present, and future. AIDS Res Treat 2012, 2012:595762.
39. Price AL, Patterson NJ, Plenge RM, Weinblatt ME, Shadick NA, Reich D:
Principal components analysis corrects for stratification in genome-wide
association studies. Nat Genet 2006, 38:904–909.

Page 10 of 10

40. Svitin A, Malov S, Cherkasov N, Geerts P, Rotkevich M, Dobrynin P,
Shevchenko A, Guan L, Troyer J, Hendrickson S, Hutcheson Dilks H, Oleksyk
TK, Donfield S, Gomperts E, Jabs DA, Sezgin E, Van Natta M, Harrigan PR,
Brumme ZL, O'Brien SJ: Software and Supporting Material for: “GWATCH:
A Web Platform For Automated Gene Association Discovery Analysis”.
In GigaScience Database. 2014. http://dx.doi.org/10.5524/10.5524/100109.
doi:10.1186/2047-217X-3-18
Cite this article as: Svitin et al.: GWATCH: a web platform for automated
gene association discovery analysis. GigaScience 2014 3:18.

Submit your next manuscript to BioMed Central
and take full advantage of:
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at
www.biomedcentral.com/submit

